N-Allylcyclohexylamine → N-Allyl-N-cyclohexyl-2-[4-(3,3-diphenyl-1-propyl)piperazin-1-yl]-3-methylisonicotinamide

HRID 1796760

반응식

HRID 1796760 반응식
[C:1]1([CH:7]([C:26]2[CH:31]=[CH:30][CH:29]=[CH:28][CH:27]=2)[CH2:8][CH2:9][N:10]2[CH2:15][CH2:14][N:13]([C:16]3[C:17]([CH3:25])=[C:18]([CH:22]=[CH:23][N:24]=3)[C:19](O)=[O:20])[CH2:12][CH2:11]2)[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.[CH2:32]([NH:35][CH:36]1[CH2:41][CH2:40][CH2:39][CH2:38][CH2:37]1)[CH:33]=[CH2:34]>>[CH2:32]([N:35]([CH:36]1[CH2:41][CH2:40][CH2:39][CH2:38][CH2:37]1)[C:19](=[O:20])[C:18]1[CH:22]=[CH:23][N:24]=[C:16]([N:13]2[CH2:14][CH2:15][N:10]([CH2:9][CH2:8][CH:7]([C:26]3[CH:27]=[CH:28][CH:29]=[CH:30][CH:31]=3)[C:1]3[CH:2]=[CH:3][CH:4]=[CH:5][CH:6]=3)[CH2:11][CH2:12]2)[C:17]=1[CH3:25])[CH:33]=[CH2:34]

참가 물질

3

반응물 2

HCID 81115N-AllylcyclohexylamineHCID 221805132-[4-(3,3-Diphenyl-1-propyl)piperazin-1-yl]-3-methylisonicotinic acid

생성물 1

HCID 22180238N-Allyl-N-cyclohexyl-2-[4-(3,3-diphenyl-1-propyl)piperazin-1-yl]-3-methylisonicotinamide수율 68.1%

실험 절차

Step (d) of Example 107 was repeated, except that the compound (50 mg) prepared in step (c) of Example 109 and allylcyclohexylamine (34 mg) were used as the starting compounds. Thus, the title compound (44 mg) was obtained.

출처 및 근거

ORD 기록
ord-d7332c65ab8547bfbf7efe6f6ceb66e0
출처 데이터셋
uspto-grants-2006_04
특허 번호
US07030120B2

연결된 노트

불러오는 중…